Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer

Published:2019-07 Issue:4 Volume:20 Page:e470-e479
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Voong Khinh Ranh^ORCID,Hazell Sarah Z.,Fu Wei,Hu Chen,Lin Cheng Ting,Ding Kai,Suresh Karthik,Hayman Jonathan,Hales Russell K.,Alfaifi Salem,Marrone Kristen A.,Levy Benjamin,Hann Christine L.,Ettinger David S.,Feliciano Josephine L.,Peterson Valerie,Kelly Ronan J.,Brahmer Julie R.,Forde Patrick M.,Naidoo Jarushka^ORCID

Funder

BMS

AstraZeneca

MedImmune

Bristol Myers-Squibb

Kyowa-Kirin

Novartis

GlaxoSmithKline

Merrimack Pharmaceuticals

National Cancer Institute

Eli Lily

Boehringer Ingelheim

Celgene

Lung Cancer Research Foundation

Radiation Oncology Institute

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer;Reck;N Engl J Med,2016

2. Pembrolizumab versus docetaxel for previously treated, PD-L1–positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

3. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N Engl J Med,2015

4. Toxicities of the anti–PD-1 and anti–PD-L1 immune checkpoint antibodies;Naidoo;Ann Oncol,2015

5. Interstitial lung diseases in the hospitalized patient;Disayabutr;BMC Med,2015

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC;BMC Pulmonary Medicine;2024-05-23

2. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials;PLOS ONE;2024-04-29

3. Bootstrap-quantile ridge estimator for linear regression with applications;PLOS ONE;2024-04-29

4. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer;British Journal of Cancer;2024-03-22

5. Pneumonitis after normofractionatedi Radoimmunotherapy: A method for Dose-Volume-Effect Correlation Evaluation;2024-03-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3